AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 11523124
Drug: Method 1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Method 1 (conventional procedure): oral magnesium citrate followed by glycerin enema.
Trial: 11523124
Drug: Method 2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Method 2 (new procedure): oral magnesium citrate followed by oral picosulfate and bisacodyl suppository.
Trial: 9748048
Drug: Gabapentin (300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gabapentin (300 to 2,400 mg/d)
Trial: 7820984
Drug: Intravenous clarithromycin
RxNorm normalized name: Clarithromycin
DrugBank: Clarithromycin (DB01211)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous clarithromycin infusion (1.5 mg/kg)
Trial: 3273863
Drug: One antacid
RxNorm normalized name: Acid Gone Antacid
DrugBank: Magnesium carbonate (DB09481)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: One antacid tablet (experimental)
Trial: 3273863
Drug: 5 ml
RxNorm normalized name: WATER,INHL 5 ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 ml of liquid antacid (commercial)
Trial: 3273863
Drug: 10 ml
RxNorm normalized name: Vial Empty 10 mL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 ml of liquid antacid (commercial)
Trial: 3273863
Drug: Two antacid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Two antacid tablets (experimental)
Trial: 26960538
Drug: Gadobutrol at
RxNorm normalized name: Gadobutrol
DrugBank: Gadobutrol (DB06703)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Gadobutrol at the recommended dose (0.11 mmol/kg body weight)
Trial: 26960538
Drug: Gadobutrol at
RxNorm normalized name: Gadobutrol
DrugBank: Gadobutrol (DB06703)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Gadobutrol at the recommended dose
Trial: 25775052
Drug: Bivalirudin with
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bivalirudin with a post-PCI infusion (n=735)
Trial: 25775052
Drug: Heparin alone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Heparin alone (n=729)
Trial: 25775052
Drug: Heparin plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Heparin plus tirofiban (n=730)
Trial: 21558571
Drug: Slow Reduction
RxNorm normalized name: reductic acid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Slow Reduction (SR) - 0.7% weekly weight loss
Trial: 21558571
Drug: Fast Reduction
RxNorm normalized name: reductic acid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fast Reduction (FR) - 1.4% weekly weight loss
Trial: 15648293
Drug: Induction chemotherapy
RxNorm normalized name: human sputum, Bordetella pertussis infected
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Induction chemotherapy (specific regimens not detailed)
Trial: 15648293
Drug: Chemotherapy combined
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy combined with radiotherapy (specific regimens not detailed)
Trial: 7931477
Drug: Tamoxifen 10
RxNorm normalized name: tamoxifen 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tamoxifen 10 mg twice daily by mouth for 1 year
Trial: 7931477
Drug: Cyclophosphamide 60
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cyclophosphamide 60 mg/m2/d by mouth for 1 year, methotrexate 15 mg/m2 IV weekly for 1 year, fluorouracil (5‐FU) 400 mg/m2 IV weekly for 1 year, vincristine .625 mg/m2 IV weekly for the first 10 weeks, and prednisone during weeks 1 to 10 with doses decreasing from 30 mg/m2 to 2.5 mg/m2 (CMFVP)
Trial: 7931477
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of tamoxifen and CMFVP
Trial: 26990920
Drug: Continuing medical
RxNorm normalized name: fish oil (containing omega-3 acids) Injection [Omegaven]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuing medical therapy
Trial: 25672380
Drug: EMLA (25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: EMLA (25 mg/g lidocaine and 25 mg/g prilocaine)
Trial: 25672380
Drug: Topical 2%
RxNorm normalized name: menthol topical 2% topical gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical 2% benzocaine
Trial: 23995608
Drug: Otamixaban (bolus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Otamixaban (bolus of 0.080 mg/kg followed by an infusion of 0.140 mg/kg per hour)
Trial: 16118546
Drug: Unfractionated heparin
RxNorm normalized name: Unfractionated heparin
DrugBank: Heparin (DB01109)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Unfractionated heparin plus eptifibatide
Trial: 11231385
Drug: Intravenous midazolam
RxNorm normalized name: Midazolam
DrugBank: Midazolam (DB00683)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Intravenous midazolam and intravenous meperidine
Trial: 9513074
Drug: Switching from
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Switching from five-membered-ring agents (cimetidine, ranitidine, famotidine) to roxatidine in the treatment of five-membered-ring resistant ulcers.
Trial: 9513074
Drug: Switching from
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Switching from roxatidine to five-membered-ring agents in the treatment of roxatidine-resistant ulcers.
Trial: 8296753
Drug: Conventional antiarrhythmic
RxNorm normalized name: ANTIARRHYTHMICS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional antiarrhythmic drugs
Trial: 2498141
Drug: Tocainide (400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tocainide (400 mg, three times daily)
Trial: 2498141
Drug: Atenolol (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atenolol (100 mg, once daily)
Trial: 2498141
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of Atenolol and Tocainide
Trial: 4929685
Drug: 2.5 mg
RxNorm normalized name: biotin 2.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2.5 mg phenazocine hydrobromide (Narphen)
Trial: 4929685
Drug: 10 mg
RxNorm normalized name: biotin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg morphine sulphate
Trial: 29220855
Drug: NOAC therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NOAC therapy (dabigatran 150 mg BID, apixaban 5 mg BID, dabigatran 110 mg BID, rivaroxaban 20 mg OD, rivaroxaban 15 mg OD, apixaban 2.5 mg OD)
Trial: 28059799
Drug: B&L Group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: B&L Group therapy (Ben‐Yishay & Lakin model)
Trial: 28059799
Drug: S&M Group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: S&M Group therapy (Sohlberg & Mateer model)
Trial: 26678641
Drug: Colchicine 1
RxNorm normalized name: colchicine 1 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Colchicine 1 mg/d for 2 weeks
Trial: 26678641
Drug: Placebo (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (1 tablet for 2 weeks)
Trial: 18312153
Drug: Spironolactone 25
RxNorm normalized name: spironolactone 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Spironolactone 25 mg b.i.d. (n = 17)
Trial: 18312153
Drug: Eplerenone 25
RxNorm normalized name: eplerenone 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Eplerenone 25 mg b.i.d. (n = 17)
Trial: 7066166
Drug: Spironolactone 400
RxNorm normalized name: Spironolactone
DrugBank: Spironolactone (DB00421)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Spironolactone 400 mg
Trial: 18312153
Drug: Eplerenone 150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Eplerenone 150 mg
Trial: 12672180
Drug: Recombinant human
RxNorm normalized name: Recombinant human TNF
DrugBank: Etanercept (DB00005)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Recombinant human IL-10 treatment
Trial: 12672180
Drug: In vitro
RxNorm normalized name: glucuronidase in vitro test
FDA approved: no
EMA approved: no
PMDA approved: no
Description: In vitro IL-10 treatment
Trial: 10989856
Drug: Midazolam (30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Midazolam (30 ng/mL) co-administered with ketamine
Trial: 10989856
Drug: Ketamine (50,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ketamine (50, 100, or 150 ng/mL)
Trial: 10989856
Drug: Co-administration of
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Co-administration of Midazolam and Ketamine
Trial: 9183229
Drug: Conjugated estrogens,
RxNorm normalized name: synthetic conjugated estrogens, A
DrugBank: Synthetic Conjugated Estrogens, A (DB09317)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conjugated estrogens, 0.625 mg/d
Trial: 9183229
Drug: Pravastatin sodium,
RxNorm normalized name: Pravastatin Sodium, 10 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pravastatin sodium, 20 mg/d
Trial: 24548114
Drug: Aspirin before
RxNorm normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Aspirin before and after exercise (AA)
Trial: 24548114
Drug: Aspirin before
RxNorm normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Aspirin before and placebo after exercise (AP)
Trial: 24548114
Drug: Placebo before
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo before and aspirin after exercise (PA)
Trial: 20186295
Drug: Propofol 0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propofol 0.5 mg.kg(‐1)
Trial: 17914519
Drug: Etomidate 0.1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Etomidate 0.1 mg.kg(‐1)
Trial: 12100298
Drug: Budesonide (140
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Budesonide (140 microg once daily)
Trial: 12100298
Drug: Fluticasone (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluticasone (200 microg once daily)
Trial: 2382243
Drug: Inhaled frusemide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled frusemide (40 mg in 4 ml buffered saline)
Trial: 2382243
Drug: Placebo (4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (4 ml of diluent solution)
Trial: 24010954
Drug: Intensive periodontal
RxNorm normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intensive periodontal treatment (scaling and root planing)
Trial: 24010954
Drug: Community periodontal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Community periodontal treatment (one session of supragingival plaque removal)
Trial: 17341712
Drug: Estrogen plus
RxNorm normalized name: estrogens
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Estrogen plus progestin (0.625 mg of oral conjugated equine estrogen and 2.5 mg of medroxyprogesterone acetate)
Trial: 11677862
Drug: Homeopathic drugs
RxNorm normalized name: homeopathic drugs
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Homeopathic drugs (Homéogène 46 and Sédatif PC)
Trial: 9366318
Drug: Intravesical capsaicin
RxNorm normalized name: Capsaicin
DrugBank: Capsaicin (DB06774)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravesical capsaicin (1 to 2 mmol/l. in 30% ethanol in saline)
Trial: 2892658
Drug: Famotidine (40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Famotidine (40 mg daily)
Trial: 31308360
Drug: Delayed-release nutrient
RxNorm normalized name: Votrient
DrugBank: Pazopanib (DB06589)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Delayed-release nutrient (DRN)
Trial: 17036388
Drug: Polyethylene glycol
RxNorm normalized name: Polyethylene Glycol
DrugBank: Polyethylene glycol (DB09287)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Polyethylene glycol electrolyte solution on the same day as colonoscopy
Trial: 17036388
Drug: Polyethylene glycol
RxNorm normalized name: Polyethylene Glycol
DrugBank: Polyethylene glycol (DB09287)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Polyethylene glycol electrolyte solution on the day prior to colonoscopy
Trial: 17036388
Drug: Preparation on
RxNorm normalized name: cranberry preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Preparation on the same day as colonoscopy
Trial: 17036388
Drug: Preparation on
RxNorm normalized name: cranberry preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Preparation on the day prior to colonoscopy
Trial: 15231912
Drug: Multivitamins with
RxNorm normalized name: MULTIVITAMINS WITH MINERALS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multivitamins with iron (10 mg/day) for 3 months
Trial: 15231912
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (standard-dose multivitamins without iron)
Trial: 11231988
Drug: No lipid
RxNorm normalized name: guggul lipids
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No lipid infusion (control)
Trial: 11210867
Drug: Ranitidine at
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ranitidine at a dosage of 1 mg/kg per day intravenously for 20 days
Trial: 11783268
Drug: Qingkailing injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Qingkailing injection (QKLI) 120 ml/d
Trial: 11783268
Drug: Qingkailing injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Qingkailing injection (QKLI) 160 ml/d
Trial: 11783268
Drug: Qingkailing injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Qingkailing injection (QKLI) 200 ml/d
Trial: 11783268
Drug: Lincomycin 1.8
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lincomycin 1.8 g/d
Trial: 11783268
Drug: Qingkailing injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Qingkailing injection (QKLI)
Trial: 2472994
Drug: Glucagon and
RxNorm normalized name: Glucagon
DrugBank: Glucagon (DB00040)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Glucagon and insulin therapy
Trial: 362955
Drug: Levamisole (50-150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Levamisole (50-150 mg)
Trial: 31757095
Drug: Marine n-3
RxNorm normalized name: 22:6(n-3)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Marine n-3 PUFA (three 1 g capsules containing 460 mg/g EPA and 380 mg/g DHA) for 44 weeks
Trial: 28440817
Drug: Sulpiride (800
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sulpiride (800 mg p.o.)
Trial: 25922903
Drug: Placebo nitrite
RxNorm normalized name: Nitrite
DrugBank: Nitrite (DB12529)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo nitrite cream and placebo citric acid cream applied twice daily
Trial: 25922903
Drug: Low-dose treatment
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose treatment (sodium nitrite, 3%, with citric acid, 4.5%, creams applied twice daily)
Trial: 25922903
Drug: Middle-dose treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Middle-dose treatment (sodium nitrite, 6%, with citric acid, 9%, creams applied once daily at night, with placebo applied in the morning)
Trial: 25922903
Drug: High-dose treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose treatment (sodium nitrite, 6%, with citric acid, 9%, creams applied twice daily)
Trial: 24607004
Drug: High Dose
RxNorm normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High Dose (HD) - 5×10(8) TCID50 of modified vaccinia Ankara
Trial: 24607004
Drug: Standard Dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard Dose (SD) - 1×10(8) TCID50 of modified vaccinia Ankara (2 doses)
Trial: 18074029
Drug: Amantadine 100
RxNorm normalized name: amantadine 100 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amantadine 100 mg po bid
Trial: 18074029
Drug: Oseltamivir 75
RxNorm normalized name: oseltamivir 75 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oseltamivir 75 mg po bid
Trial: 18074029
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of amantadine and oseltamivir
Trial: 11170731
Drug: Dysport (botulinum
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dysport (botulinum neurotoxin type A) diluted to a final concentration of 50 U/ml, low-dose treatment cut by approximately 70%
Trial: 11170731
Drug: Recommended higher
RxNorm normalized name: salicylic acid
DrugBank: Salicylic acid (DB00936)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Recommended higher doses of Dysport
Trial: 8026092
Drug: Topical aural
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical aural antibiotic therapy (7-day course)
Trial: 8026092
Drug: Topical aural
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical aural antibiotic therapy administered by someone other than the patient
Trial: 960794
Drug: Caffeine solution
RxNorm normalized name: Caffeine
DrugBank: Caffeine (DB00201)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Caffeine solution
Trial: 31498783
Drug: Dexmedetomidine (0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexmedetomidine (0.5 μg/kg 10-minutes before induction and 0.5 μg/kg/hour maintenance infusion until end of operation)
Trial: 26264648
Drug: Group cognitive
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group cognitive behavior therapy (gCBT)
Trial: 23118022
Drug: Antidopaminergic treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antidopaminergic treatment (aripiprazole, haloperidol, or reserpine)
Trial: 19932779
Drug: Combination therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination therapy (telmisartan + ramipril)
Trial: 17684878
Drug: 15 mg
RxNorm normalized name: papain 15 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 15 mg of hyperbaric ropivacaine with 0.1 mg of preservative-free morphine and 0.01 mg fentanyl
Trial: 17684878
Drug: 11.25 mg
RxNorm normalized name: phentermine 11.25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 11.25 mg of hyperbaric bupivacaine with 0.1 mg of preservative-free morphine and 0.01 mg fentanyl
Trial: 11238483
Drug: 50 g
RxNorm normalized name: glucose 50 g/296 mL oral liquid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50 g protein in the form of very lean beef
Trial: 9669811
Drug: Hybrid chemotherapy
RxNorm normalized name: Amaranthus hybridus pollen
DrugBank: Amaranthus hybridus pollen (DB15503)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hybrid chemotherapy (HYB) - CAV/PVP, 3-drug CAV on Day 1 and 2-drug PVP on Day 8, repeated every 4 weeks for up to 6 cycles.
Trial: 9669811
Drug: Sequential chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sequential chemotherapy (SEQ) - CAV followed by PVP, 3 cycles each every 4 weeks, delivered on Days 1 and 8.
Trial: 3261647
Drug: Surgical treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Surgical treatment (ejection fractions 0.30 to 0.49)
Trial: 3261647
Drug: Medical treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medical treatment (ejection fractions > 0.69)
Trial: 31665005
Drug: Advanced disease
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Advanced disease with no treatment
Trial: 27225598
Drug: Pulmonary rehabilitation
RxNorm normalized name: Lobaria pulmonaria extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pulmonary rehabilitation plus tablet (tablet group)
Trial: 24114194
Drug: Sustained release
RxNorm normalized name: Sustained Release Buccal Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sustained release (SR) formulations of ONO-5334
Trial: 24114194
Drug: Sustained release
RxNorm normalized name: Sustained Release Buccal Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sustained release (SR) tablets of ONO-5334
Trial: 22797880
Drug: Oral pregabalin,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral pregabalin, 75 mg q12 h for five consecutive days starting the night before surgery
Trial: 17805093
Drug: Simulated LH+TL
RxNorm normalized name: LH
DrugBank: Luteinizing hormone (DB14741)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Simulated LH+TL devices (e.g., nitrogen apartments, hypoxic tents, hypoxicator devices)
Trial: 15154878
Drug: Etidronate 200
RxNorm normalized name: etidronate 200 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Etidronate 200 mg orally before sleep on dialysis days (3 times per week)
Trial: 16556138
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (no etidronate treatment)
Trial: 11666124
Drug: Total triterpenic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Total triterpenic fraction of Centella asiatica (TTFCA) 60 mg twice daily for 6 months
Trial: 22174166
Drug: No treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No treatment (second control group)
Trial: 3058442
Drug: Domperidone (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Domperidone (20 mg before meals and at bedtime for six weeks)
Trial: 3058442
Drug: Placebo (oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (oral for six weeks)
Trial: 28937255
Drug: Oral administration
RxNorm normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral administration of whey proteins (OWIST)
Trial: 26525617
Drug: Low calorie
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low calorie diet therapy (LCDT)
Trial: 19141576
Drug: Febuxostat 80
RxNorm normalized name: febuxostat 80 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Febuxostat 80 mg daily (with adjustments to 40 mg or 120 mg as needed)
Trial: 17583188
Drug: Perindopril/Indapamide combination
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Perindopril/Indapamide combination (Per 2 mg/Ind 0.625 mg) for 3-6 months
Trial: 11174052
Drug: riluzole 150
RxNorm normalized name: Riluzole
DrugBank: Riluzole (DB00740)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: riluzole 150 mg
Trial: 9296037
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of malocid-sulfadiazine